Tumor-restricted activation of Vγ9Vδ2 T cells via bispecific Evobodies: a novel strategy for safe and potent immunotherapy in ovarian cancer

Tumor-restricted activation of Vγ9Vδ2 T cells via bispecific Evobodies: a novel strategy for safe and potent immunotherapy in ovarian cancer

IntroductionVγ9Vδ2 T cells have been clinically evaluated—both in vivo and ex vivo—for their efficacy against solid tumors over several decades. Although recent therapeutic approaches have renewed hope, significant and reproducible benefits for patients with solid tumors remains to be demonstrated.M...

Full description

Saved in:
Bibliographic Details
Main Authors: Hans-Heinrich Oberg, Malte Deseke, Steffen Krohn, Dorothee Winterberg, Matthias Peipp, Dirk Bauerschlag, Klaus-Peter Künkele, Daniela Wesch, Christoph Baumann
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Immunology
Subjects:
Vγ9Vδ2 T cells
FOLR1
evobody
ovarian cancer
immunotherapy
BTN3A
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1628501/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items